Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Meningococcal Polysaccharide Diphtheria Protein Conjugate · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Vaccinated at Age 9 and 12 Months | EXPERIMENTAL | Participants received Menactra® vaccine at 9 and 12 Months of age |
| Vaccinated at Age 9 and 15 Months | EXPERIMENTAL | Participants received Menactra® vaccine at 9 and 15 Months of age |
| Vaccinated at Age 12 and 15 Months | EXPERIMENTAL | Participants received Menactra® vaccine at Age 12 and 12 Months of age |
| Vaccinated at Age 15 Months | EXPERIMENTAL | Participants received Menactra® vaccine at 15 Months of age |
| Vaccinated at Age 18 Months | EXPERIMENTAL | Participants received Menactra® vaccine at 18 Months of age |
| Vaccinated at Age 3 Years to <6 Years | ACTIVE_COMPARATOR | Participants received Menomune® vaccine at Age 3 years to \<6 years of age |
| Name | Type | Description |
|---|---|---|
| Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®) | BIOLOGICAL | 0.5 mL, Intramuscular (at age 9 and 12 months) |
| A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®) | BIOLOGICAL | 0.5 mL, Subcutaneous (at 3 years to \<6 years of age) |
Inclusion Criteria : * Aged either 9, 12, 15 or 18 months of age or 3 to \< 6 years of age on the day of inclusion. * Informed consent form that has been approved by the site's Institutional Review Board (IRB) and signed by the parent or legal guardian * Able to attend all scheduled visits and to c...
Meningococcal Polysaccharide Diphtheria Protein Conjugate is used for the prevention of meningitis and meningococcal infection. It is a vaccine developed by Sanofi. The only clinical trial of this product enrolled toddlers 9 to 18 months of age in the United States.
Meningococcal Polysaccharide Diphtheria Protein Conjugate is made by Sanofi, which trades under the ticker SNY. Sanofi is the developer of this vaccine candidate.
Meningococcal Polysaccharide Diphtheria Protein Conjugate is in Phase 2 development. It is an investigational product and is not approved. The Phase 2 trial, NCT00643916, has been completed.
Meningococcal Polysaccharide Diphtheria Protein Conjugate has been studied in one clinical trial, NCT00643916, titled Study of a Tetravalent Meningococcal Diphtheria Toxoid Conjugate Vaccine in Toddlers 9 to 18 Months of Age. The Phase 2 trial was completed and enrolled 378 participants in the United States.
Yes, Meningococcal Polysaccharide Diphtheria Protein Conjugate is also known as Menactra. Menactra is the brand name for this Sanofi product.